Undisclosed B7-H6 targeted γδ CAR T / Adicet Bio - LARVOL DELTA

Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (Businesswire) - "ADI-925, a novel engineered chimeric adaptor (CAd) gamma delta T cell product candidate, is engineered to provide broad antitumor activity in multiple heme and solid malignancies; IND submission expected second half of 2023; Four differentiated chimeric antigen receptor (CAR) and CAd programs targeting several hematologic and solid malignancies featured at SITC; Company to unveil new details from pipeline during R&D webcast event Thursday, November 10, 2022 at 9:00 a.m. ET....Adicet Bio, Inc..announced that positive preclinical data from four new pipeline programs will be featured at poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting on November 10-11, 2022."

IND • Pipeline update • Preclinical • Genito-urinary Cancer • Hematological Malignancies • Oncology • Prostate Cancer • Solid Tumor

Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (Businesswire) - "Adicet Bio, Inc...announced four preclinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA."

Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor